| Martin Van Sloan, DPM | |
|
1150 N 18th St, Ste 206, Abilene, TX 79601 | |
| (325) 695-1890 | |
| (325) 695-1665 |
| Full Name | Martin Van Sloan |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 41 Years |
| Location | 1150 N 18th St, Abilene, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639178387 | NPI | - | NPPES |
| 004395004 | Other | TX | AETNA |
| 00FJ64 | Other | TX | BLUE CROSS BLUE SHIELD |
| 0187064-01 | Medicaid | TX | |
| 0288250001 | Other | TX | DMERC NSC |
| 0288250002 | Other | TX | DMERC NSC ROCKWALL |
| 124202100 | Other | TX | FIRSTCARE |
| 480004770 | Other | TX | RAILROAD MEDICARE |
| Provider Name | Health And Human Services Commission |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356414692 PECOS PAC ID: 2163795824 Enrollment ID: O20170908001058 |
News Archive
Ongoing research at Missouri University of Science and Technology has uncovered a new method for the early detection of cancer with the potential to save millions of lives.
An improved approach to gene therapy may one day treat some of the nearly 200 inherited forms of blindness, scientists at Washington University School of Medicine in St. Louis suggest.
A new report from Oxfam and 62 other non-governmental organizations and health groups finds that international goals aiming to reduce child and maternal mortality rates are "desperately off track," with four million babies around the world dying annually within 28 days of birth, Agence France-Press reports (9/13).
On September 4th Dr. Phillip C. Hoopes, Jr., a surgeon at Hoopes Vision, successfully placed a light adjustable intraocular lens implant in a cataract patient as part of a new FDA clinical study.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Martin Van Sloan, DPM 1150 N 18th St, Ste 206, Abilene, TX 79601-2931 Ph: (325) 695-1890 | Martin Van Sloan, DPM 1150 N 18th St, Ste 206, Abilene, TX 79601 Ph: (325) 695-1890 |
News Archive
Ongoing research at Missouri University of Science and Technology has uncovered a new method for the early detection of cancer with the potential to save millions of lives.
An improved approach to gene therapy may one day treat some of the nearly 200 inherited forms of blindness, scientists at Washington University School of Medicine in St. Louis suggest.
A new report from Oxfam and 62 other non-governmental organizations and health groups finds that international goals aiming to reduce child and maternal mortality rates are "desperately off track," with four million babies around the world dying annually within 28 days of birth, Agence France-Press reports (9/13).
On September 4th Dr. Phillip C. Hoopes, Jr., a surgeon at Hoopes Vision, successfully placed a light adjustable intraocular lens implant in a cataract patient as part of a new FDA clinical study.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
› Verified 3 days ago
Beil Cory Brown, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1665 Antilley Rd., Suite 210, Abilene, TX 79606 Phone: 325-793-5135 Fax: 325-793-5136 | |
Abilene Diagnostic Clinics Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 6250 Regional Plz Ste 1016, Abilene, TX 79606 Phone: 325-437-8655 Fax: 325-437-8647 | |
Abilene Diagnostic Clinics Podiatrist Medicare: Medicare Enrolled Practice Location: 1665 Antilley Rd Ste 210, Abilene, TX 79606 Phone: 325-437-8647 Fax: 325-793-5107 | |
Danny E Wheat Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1401 Ambler Ave, Suite 102, Abilene, TX 79601 Phone: 325-670-3338 Fax: 325-670-4078 | |
Abilene Family Foot Center, P.a. Podiatrist Medicare: Medicare Enrolled Practice Location: 2501 S Willis St, Ste A, Abilene, TX 79605 Phone: 325-695-8990 Fax: 325-695-0901 | |
Dr. Galen Chris Albritton, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2501 S Willis St, Ste A, Abilene, TX 79605 Phone: 325-695-8990 Fax: 325-695-0901 | |
Martin V. Sloan, Dpm Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1150 N 18th St, Suite 206, Abilene, TX 79601 Phone: 325-695-1890 Fax: 325-695-1665 |